Skip to main content
Erschienen in: Endocrine 2/2024

07.11.2023 | Original Article

Predictive model for the progression of inactive thyroid eye disease: a retrospective study

verfasst von: Lingzi Qi, Xuefei Song, Yinwei Li, Jing Sun, Huifang Zhou, Xianqun Fan

Erschienen in: Endocrine | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aimed to develop a model for predicting the progression of inactive thyroid eye disease (TED).

Methods

We retrospectively analyzed 107 patients with inactive TED, who did not receive any TED treatment during the follow-up period of 3–6 months. A multivariable regression analysis was employed to examine the clinical risk factors influencing the progress of TED and a predictive model based on risk factors was established.

Results

Seventeen (15.9%) patients had progressed at the last observation. Male (p = 0.024), having smoking history (p = 0.009), compound indicator combined the duration of TED and immunosuppressive treatment history before 3 months (p = 0.026) and more severe diplopia (p = 0.015) were found to be the potential risk factors for progression. Among the subset of patients who exhibited progression, there was a notable escalation in the severity of proptosis (p = 0.021), margin reflex distance-1 (p = 0.031), and clinical activity score (p = 0.011). The multivariable stepwise regression analysis identified positive smoking history as well as untreated and having a duration of TED > 12 months as independent risk factors of TED progression. A predictive model including these risk factors was built, with the AUC (Area Under Curve) score of 0.783.

Conclusions

The predictors of TED progression include smoking history and composite indicators of duration time and treatment history. Our model may provide recommendations for immunosuppressive therapy and prognostic predictions for inactive TED patients preparing for surgery.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Lei, C. et al. Facial expression of patients with Graves’ orbitopathy. J. Endocrinol. Invest. 2023 Lei, C. et al. Facial expression of patients with Graves’ orbitopathy. J. Endocrinol. Invest. 2023
3.
Zurück zum Zitat B. Du et al. Clinical features and clinical course of thyroid-associated ophthalmopathy: a case series of 3620 Chinese cases. Eye (Lond.) 35(8), 2294–2301 (2021)CrossRefPubMed B. Du et al. Clinical features and clinical course of thyroid-associated ophthalmopathy: a case series of 3620 Chinese cases. Eye (Lond.) 35(8), 2294–2301 (2021)CrossRefPubMed
4.
Zurück zum Zitat X. Huang et al. The significance of ophthalmological features in diagnosis of thyroid-associated ophthalmopathy. Biomed. Eng. Online 22(1), 7 (2023)CrossRefPubMedPubMedCentral X. Huang et al. The significance of ophthalmological features in diagnosis of thyroid-associated ophthalmopathy. Biomed. Eng. Online 22(1), 7 (2023)CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Q. Li et al. Clinical characteristics of moderate-to-severe thyroid associated ophthalmopathy in 354 Chinese cases. PLoS One 12(5), e0176064 (2017)CrossRefPubMedPubMedCentral Q. Li et al. Clinical characteristics of moderate-to-severe thyroid associated ophthalmopathy in 354 Chinese cases. PLoS One 12(5), e0176064 (2017)CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat F.F. Rundle, C.W. Wilson, Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy. Clin. Sci. 5(3-4), 177–194 (1945)PubMed F.F. Rundle, C.W. Wilson, Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy. Clin. Sci. 5(3-4), 177–194 (1945)PubMed
7.
Zurück zum Zitat R.S. Douglas et al. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology 129(4), 438–449 (2022)CrossRefPubMed R.S. Douglas et al. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology 129(4), 438–449 (2022)CrossRefPubMed
8.
Zurück zum Zitat H.Y. Ahn, J. Lee, J.K. Lee, Predictive model for Graves’ ophthalmopathy in patients with new-onset Graves’ disease. Thyroid 32(12), 1559–1567 (2022)CrossRefPubMed H.Y. Ahn, J. Lee, J.K. Lee, Predictive model for Graves’ ophthalmopathy in patients with new-onset Graves’ disease. Thyroid 32(12), 1559–1567 (2022)CrossRefPubMed
9.
Zurück zum Zitat W. Wiersinga et al. Predictive score for the development or progression of Graves’ orbitopathy in patients with newly diagnosed Graves’ hyperthyroidism. Eur. J. Endocrinol. 178(6), 635–643 (2018)CrossRefPubMed W. Wiersinga et al. Predictive score for the development or progression of Graves’ orbitopathy in patients with newly diagnosed Graves’ hyperthyroidism. Eur. J. Endocrinol. 178(6), 635–643 (2018)CrossRefPubMed
10.
Zurück zum Zitat H.J. Byeon et al. Preoperative risk factors for proptosis recurrence after rehabilitative orbital decompression in Graves’ orbitopathy patients. Am. J. Ophthalmol. 2023 H.J. Byeon et al. Preoperative risk factors for proptosis recurrence after rehabilitative orbital decompression in Graves’ orbitopathy patients. Am. J. Ophthalmol. 2023
11.
Zurück zum Zitat L. Bartalena et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur. J. Endocrinol. 185(4), G43–g67 (2021)CrossRefPubMed L. Bartalena et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur. J. Endocrinol. 185(4), G43–g67 (2021)CrossRefPubMed
12.
Zurück zum Zitat Y. Wang et al. A single-center retrospective study of factors related to the effects of intravenous glucocorticoid therapy in moderate-to-severe and active thyroid-associated ophthalmopathy. BMC Endocr. Disord. 18(1), 13 (2018)CrossRefPubMedPubMedCentral Y. Wang et al. A single-center retrospective study of factors related to the effects of intravenous glucocorticoid therapy in moderate-to-severe and active thyroid-associated ophthalmopathy. BMC Endocr. Disord. 18(1), 13 (2018)CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat R.S. Bahn, C.A. Gorman, Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol. Metab. Clin. North Am. 16(2), 391–407 (1987)CrossRefPubMed R.S. Bahn, C.A. Gorman, Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol. Metab. Clin. North Am. 16(2), 391–407 (1987)CrossRefPubMed
14.
Zurück zum Zitat P. Perros et al. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves’ ophthalmopathy. J. Clin. Endocrinol. Metab. 90(9), 5321–5323 (2005)CrossRefPubMed P. Perros et al. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves’ ophthalmopathy. J. Clin. Endocrinol. Metab. 90(9), 5321–5323 (2005)CrossRefPubMed
15.
16.
Zurück zum Zitat L. Bartalena et al. More on smoking habits and Graves’ ophthalmopathy. J. Endocrinol. Invest 12(10), 733–737 (1989)CrossRef L. Bartalena et al. More on smoking habits and Graves’ ophthalmopathy. J. Endocrinol. Invest 12(10), 733–737 (1989)CrossRef
17.
Zurück zum Zitat J. Pfeilschifter, R. Ziegler, Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin. Endocrinol. (Oxf.) 45(4), 477–481 (1996)CrossRefPubMed J. Pfeilschifter, R. Ziegler, Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin. Endocrinol. (Oxf.) 45(4), 477–481 (1996)CrossRefPubMed
18.
Zurück zum Zitat M.F. Prummel, W.M. Wiersinga, Smoking and risk of Graves’ disease. Jama 269(4), 479–482 (1993)CrossRefPubMed M.F. Prummel, W.M. Wiersinga, Smoking and risk of Graves’ disease. Jama 269(4), 479–482 (1993)CrossRefPubMed
19.
Zurück zum Zitat M.H. Lee et al. Risk factors of thyroid eye disease. Endocr. Pr. 27(3), 245–253 (2021)CrossRef M.H. Lee et al. Risk factors of thyroid eye disease. Endocr. Pr. 27(3), 245–253 (2021)CrossRef
20.
Zurück zum Zitat H.C. Kau et al. Cigarette smoke extract-induced oxidative stress and fibrosis-related genes expression in orbital fibroblasts from patients with Graves’ ophthalmopathy. Oxid. Med. Cell Longev. 2016, 4676289 (2016)CrossRefPubMedPubMedCentral H.C. Kau et al. Cigarette smoke extract-induced oxidative stress and fibrosis-related genes expression in orbital fibroblasts from patients with Graves’ ophthalmopathy. Oxid. Med. Cell Longev. 2016, 4676289 (2016)CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat B.T. Johnson, E. Jameyfield, V.K. Aakalu, Optic neuropathy and diplopia from thyroid eye disease: update on pathophysiology and treatment. Curr. Opin. Neurol. 34(1), 116–121 (2021)CrossRefPubMedPubMedCentral B.T. Johnson, E. Jameyfield, V.K. Aakalu, Optic neuropathy and diplopia from thyroid eye disease: update on pathophysiology and treatment. Curr. Opin. Neurol. 34(1), 116–121 (2021)CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat S.H. Yu et al. Clinical Implications of Immunoglobulin G4 to Graves’ Ophthalmopathy. Thyroid 27(9), 1185–1193 (2017)CrossRefPubMed S.H. Yu et al. Clinical Implications of Immunoglobulin G4 to Graves’ Ophthalmopathy. Thyroid 27(9), 1185–1193 (2017)CrossRefPubMed
23.
Zurück zum Zitat T. Diana, G.J. Kahaly, Thyroid stimulating hormone receptor antibodies in thyroid eye disease-methodology and clinical applications. Ophthalmic Plast. Reconstr. Surg. 34(4S Suppl 1), S13–s19 (2018)CrossRefPubMed T. Diana, G.J. Kahaly, Thyroid stimulating hormone receptor antibodies in thyroid eye disease-methodology and clinical applications. Ophthalmic Plast. Reconstr. Surg. 34(4S Suppl 1), S13–s19 (2018)CrossRefPubMed
24.
Zurück zum Zitat J.D. Stein et al. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol. 133(3), 290–296 (2015)CrossRefPubMedPubMedCentral J.D. Stein et al. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol. 133(3), 290–296 (2015)CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat A. Nilsson, K. Tsoumani, T. Planck, Statins decrease the risk of orbitopathy in newly diagnosed patients with Graves disease. J. Clin. Endocrinol. Metab. 106(5), 1325–1332 (2021)CrossRefPubMed A. Nilsson, K. Tsoumani, T. Planck, Statins decrease the risk of orbitopathy in newly diagnosed patients with Graves disease. J. Clin. Endocrinol. Metab. 106(5), 1325–1332 (2021)CrossRefPubMed
Metadaten
Titel
Predictive model for the progression of inactive thyroid eye disease: a retrospective study
verfasst von
Lingzi Qi
Xuefei Song
Yinwei Li
Jing Sun
Huifang Zhou
Xianqun Fan
Publikationsdatum
07.11.2023
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2024
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-023-03582-6

Weitere Artikel der Ausgabe 2/2024

Endocrine 2/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.